Search results
Results From The WOW.Com Content Network
Amlodipine works partly by vasodilation (relaxing the arteries and increasing their diameter). [10] It is a long-acting calcium channel blocker of the dihydropyridine type. [10] Amlodipine was patented in 1982, and approved for medical use in 1990. [12] It is on the World Health Organization's List of Essential Medicines. [13]
Amlodipine/olmesartan, sold under the brand name Azor, among others is a fixed-dose combination medication used to treat high blood pressure. [5] It contains amlodipine , as the besilate, a dihydropyridine calcium channel blocker , and olmesartan medoxomil , an angiotensin II receptor blocker .
Patient age, associated clinical conditions and end-organ damage also play a part in determining dosage and type of medication administered. [3] The several classes of antihypertensives differ in side effect profiles, ability to prevent endpoints, and cost.
The drug combination aliskiren/amlodipine (INNs, trade names Tekamlo and Rasilamlo) is an antihypertensive. Clinical trials have shown it to be more effective than amlodipine on its own, [ 1 ] with a high dosing regime (aliskiren 300 mg/amlodipine 10 mg) being more effective than olmesartan/amlodipine with comparable tolerability.
Nutritional problems are also frequently seen in cancer patients at diagnosis and through chemotherapy treatment. Research suggests that in children and young people undergoing cancer treatment, parenteral nutrition may help with this leading to weight gain and increased calorie and protein intake, when compared to enteral nutrition.
CAR-T treatment generally involves extracting disease-fighting white blood cells known as T-cells from a patient, re-engineering them to attack cancer and infusing them back into the body.
It contains olmesartan medoxomil, an angiotensin II receptor blocker, amlodipine, as the besilate, a calcium channel blocker, and hydrochlorothiazide, a thiazide diuretic. [3] It is taken by mouth . [ 3 ]
"FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekturna)". U.S. Food and Drug Administration (FDA) . 29 June 2021. v